Document:

Amendment of Agreement, dated September 11, 2007

 Exhibit 10.4 
 Inspire Pharmaceuticals, Inc. 
 4222 Emperor Boulevard, Suite 200 
 Durham, North Carolina 27703-8466 
 September 11, 2007 
 R. Kim Brazzell, Ph.D., 
 127
Grande Ave 
 Morrisville, North Carolina 27560 
 Re: Amendment of Agreement dated August 2, 2004 
 Dear Kim: 
 I am writing this letter in relation to the Agreement (the “Agreement”) dated August 2, 2004 by and between you and Inspire
Pharmaceuticals, Inc. (the “Company”), relating to change in control severance arrangements. As you may recall, the Agreement is automatically extended on an annual basis unless notice is provided at least 6 months prior to the anniversary
of the termination date of the initial one-year term under the Agreement. 
 The Compensation Committee of the Board of Directors of the
Company (the “Compensation Committee”) has reviewed the existing change of control agreements between the Company and each of its executive officers and well as current trends relating to change of control arrangements for executive
officers. As part of that review, the Compensation Committee has reviewed change of control arrangements made by other companies and has received input and recommendations from an independent third-party compensation consultant. As a result, the
Compensation Committee has determined that it is in the best interest of the Company and its stockholders to prepare and implement a new change in control severance policy to be effective March 29, 2008, which is the date of termination of the
change in control severance agreements between the Company and most of its executive officers. 
 In relation to such plan, the Compensation
Committee intends to inform the other executive officers that their change of control severance agreements will expire on March 29, 2008, in accordance with the terms of their respective agreements. Your Agreement does not expire on
March 29, 2008, but rather on a different timetable associated with the date you initially entered into the Agreement. 
 Notwithstanding Section 2 of the Agreement, the Compensation Committee, on behalf of the Company, requests that you agree to amend the term of the Agreement so that it expires on March 29, 2008. Please acknowledge your agreement
to such amendment by signing and dating this letter in the space provided below. Except as set forth in this letter with respect to the term of the Agreement, the Agreement shall remain in effect in accordance with its terms. 

			
	Sincerely,
		
	By:	 	 /s/ Richard S. Kent

		 	Richard S. Kent, M.D.,
		 	Chairman, Compensation Committee

 Acknowledged and Agreed: 
  

	
	 /s/ R K Brazzell

	R. Kim Brazzell, Ph.D.

 Dated: September 12, 2007 
 cc: Kenneth B. Lee, Chairman of the BoardTermination of Agreement, dated September 11, 2007

 Exhibit 10.5 
 Inspire Pharmaceuticals, Inc. 
 4222 Emperor Boulevard, Suite 200 
 Durham, North Carolina 27703-8466 
 September 11, 2007 
 Joseph M. Spagnardi, 
 36
Winding Ridge Road 
 Durham, North Carolina 27713 
 Re: Termination of Agreement dated March 2, 2006 
 Dear Joe: 
 I am writing this letter in relation to the Agreement (the “Agreement”) dated March 2, 2006 by and between you and Inspire Pharmaceuticals,
Inc. (the “Company”), relating to change in control severance arrangements. As you may recall, the Agreement is automatically extended on an annual basis unless notice is provided at least 6 months prior to the anniversary of the
termination date of the initial one-year term under the Agreement. 
 The Compensation Committee of the Board of Directors of the Company
(the “Compensation Committee”) has reviewed the existing change of control agreements between the Company and each of its executive officers and well as current trends relating to change of control arrangements for executive officers. As
part of that review, the Compensation Committee has reviewed change of control arrangements made by other companies and has received input and recommendations from an independent third-party compensation consultant. As a result, the Compensation
Committee has determined that it is in the best interest of the Company and its stockholders to prepare and implement a new change in control severance policy to be effective March 29, 2008, which is the date of termination of the change in
control severance agreements between the Company and most of its executive officers. 
 In relation to such plan, the Compensation Committee
intends to inform the other executive officers that their change of control severance agreements will expire on March 29, 2008, in accordance with the terms of their respective agreements. Your Agreement does not expire on March 29, 2008,
but rather on a different timetable associated with the date you initially entered into the Agreement. 
 Notwithstanding Section 2 of
the Agreement, the Compensation Committee, on behalf of the Company, requests that you agree to amend the term of the Agreement so that it expires on March 29, 2008. Please acknowledge your agreement to such amendment by signing and dating this
letter in the space provided below. Except as set forth in this letter with respect to the term of the Agreement, the Agreement shall remain in effect in accordance with its terms. 

			
	Sincerely,
		
	By:	 	 /s/ Richard S. Kent

		 	Richard S. Kent, M.D.,
		 	Chairman, Compensation Committee

 Acknowledged and Agreed: 
  

	
	 /s/ Joseph M. Spagnardi

	Joseph M. Spagnardi

 Dated: September 12, 2007 
 cc: Kenneth B. Lee, Chairman of the BoardTransition & Severance Agreement

 Exhibit 10.1 
 Transition And Severance Agreement 
 This Transition Agreement made as of this 19th day of
September 2007 by and between CuraGen Corporation (“CuraGen” or “Company”) and Frank M. Armstrong, MD (“Dr. Armstrong”). 
 WHEREAS, Dr. Armstrong has served as President and Chief Executive Officer of the Company pursuant to an Amended and Restated Employment Agreement dated September 1, 2006 (the “Employment
Agreement”); 
 WHEREAS, Dr. Armstrong will be transitioning from the Company; 
 WHEREAS, the Company desires to secure his continued service until December 31, 2007 to allow for the timely completion of certain
objectives and to allow for an appropriate transition of duties; and 
 WHEREAS, the Company desires to maintain his participation as
a member of its Board of Directors for a period of time thereafter; 
 NOW, THEREFORE, in consideration of the foregoing and the
mutual covenants contained herein, the parties agree as follows. 
 1. Continued Employment. Effective September 19, 2007,
Dr. Armstrong shall resign his positions as President and Chief Executive Officer of the Company and he shall assume the position of Special Adviser to the Board of Directors. Dr. Armstrong will remain in this position without reduction in
compensation or benefits through December 31, 2007 at which time he will terminate employment with the Company effective January 1, 2008 (the “Separation from Service Date”). Due to continuing business needs, Dr. Armstrong
shall serve as a non-employee member of the Company’s Board of Directors through the date of the Company’s annual meeting of stockholders in May, 2008, or such earlier date as may be agreed to by Dr. Armstrong and the Company (such
period referred to as the “Director Term”), and Dr. Armstrong will be eligible to receive compensation for such position in accordance with Company practice. For purposes of this Agreement, the term “Separation from Service”
shall have the same meaning as that accorded the term under the default rule contained in Treasury Regulation Section 1.409A-1(h)(1)(ii). 
 2. Bonus Eligibility. Dr. Armstrong shall be eligible for potential award of his annual bonus for the full year 2007 pursuant to the Executive Incentive Plan, subject to the approval of the Compensation Committee in
January, 2008, and to be paid in accordance with the terms of such plan. 
 3. Severance Benefits. Upon the Separation from
Service Date, Dr. Armstrong shall execute the Release of Claims attached hereto as Exhibit A and, conditioned on the Release of Claims becoming binding upon him, Dr. Armstrong or, in the event of Dr. Armstrong’s death, his
estate, shall be entitled to receive $519,000 as severance due to his termination without cause. This severance will be paid in a cash 

 
lump sum within 30 days after his Separation from Service Date less applicable taxes and withholdings, in accordance with the Company’s normal payroll
practices, but in no event shall payment be made until timely return and non-revocation of Attachment A. Dr. Armstrong is not eligible to receive any other payments or severance benefits under the Employment Agreement or pursuant to any other
Company plan or policy, except as specifically set forth herein. This paragraph 3 shall constitute an election as to form of payment in accordance with Section 3.02 of IRS Notice 2006-79 and an amendment to Paragraph 11C(i) of Dr
Armstrong’s employment agreement. 
 4. Health and Dental Insurance. The Separation from Service Date will serve as the
“qualifying event” under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), which shall entitle Dr. Armstrong to COBRA continuation for an 18 month period following his Separation from Service. If
Dr. Armstrong timely elects to continue medical and/or dental insurance coverage after the Separation from Service Date in accordance with the provisions of COBRA, the Company will pay the Company portion of his monthly premium payments for
twelve (12) months or until he is covered under a group health plan of another employer, whichever occurs first (the “Continuation Period”). Dr. Armstrong still will be responsible for the same employee portion of the premium
during the Continuation Period being paid by active employees participating in the same health program and paid in such manner as the Company provides. 
 5. Stock Options and Restricted Stock Awards—The terms and conditions of Dr. Armstrong’s (i) Non-Qualified Stock Option Agreement dated March 29, 2006, (ii) Restricted Stock
Agreement dated March 29, 2006 and (iii) Restricted Stock Agreement dated January 24, 2007 shall remain in full force and effect, and to the extent permitted under the terms of said agreements shall continue to vest, through and
including the last day of the Director Term. The incentive stock option granted to Dr. Armstrong on March 29, 2006, which is subject to the Incentive Stock Option Agreement dated March 29, 2006, shall cease vesting as of the
Separation from Service Date. The shares of common stock subject to Dr. Armstrong’s Restricted Stock Agreement dated May 25, 2007 shall not vest and shall be forfeited as of the Separation from Service Date. The post-termination
period for exercise of Non-qualified Stock Options shall extend from the end of the Director Term, rather than the Separation from Service date. 
 6. Termination of Benefits. All benefits, other than those provided under this Transition Agreement, will end upon the Separation from Service Date; provided, however, the Company will provide Dr. Armstrong
with return transportation to his home country following the Separation from Service Date. 
 7. Section 409A. It is
intended that all payments made under the terms of this Transition Agreement come within exceptions to Section 409A of the Internal Revenue Code of 1986, as amended (“Section 409A”), including transition guidance issued thereunder.
The Transition Agreement and all related documents shall be interpreted and administered in accordance with that intention. However, if any amount 

  

 2 

 
payable under this Transition Agreement is determined to be subject to Section 409A then such payments shall be administered in accordance with
Section 409A; provided that the Company shall not be liable for any failures under this Section 7 that result in the payment of any taxes or other amounts due under the terms of Section 409A. To the extent any amount subject to
Section 409A is to be paid or provided to Dr. Armstrong in connection with a separation from service at a time when he is considered a specified employee within the meaning of Section 409A then such payment shall not be made until the
date that is six months and one day following such separation from service, or in a lump sum to his estate upon his earlier death. 
 8.
Non-Disclosure, Non-Competition and Non-Solicitation Obligations. Dr. Armstrong acknowledges and reaffirms his obligation to keep confidential and not disclose any non-public information concerning the Company and its
clients that he acquired during the course of his employment with the Company, as stated more fully in the Employment Agreement. Dr. Armstrong further acknowledges and reaffirms his obligations as set forth in Paragraphs 6, 7 and 8 of the
Employment Agreement, which shall also remain in full force and effect; provided, however, that the reference to any “any HDAC product for oncology” shall be deleted from Paragraph 8 (A) of the Employment Agreement, except as such
prohibition would relate to Gloucester, Methylgene, Syndex and TopoTarget and any of their respective successors, joint-ventures and assigns, as to which such Paragraph 8(A) shall continue to apply for a period of 1 year from the Separation from
Service Date. 
 9. Return of Company Property. Dr. Armstrong confirms that, as of the Separation from Service Date, he
will return to the Company all keys, files, records (and copies thereof), equipment (including, but not limited to, software and printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, and any other Company-owned
property in his possession or control, and that he will leave intact all electronic Company documents, including, but not limited to, those which he developed or helped develop during his employment. Dr. Armstrong agrees that in the event that
he discovers any other Company or proprietary materials in his possession after the Separation from Service Date, he will immediately return such materials to Paul Finigan at the Company. Dr. Armstrong further confirms that he will have
cancelled all accounts for his benefit, if any, in the Company’s name, including, but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts. 
 10. Release of Claims. In consideration of the benefits provided for in this Transition Agreement, which Dr. Armstrong acknowledges he
would not otherwise be entitled to receive, and except with respect to benefits and payments under this Transition Agreement or to which Dr. Armstrong is entitled under the Company’s benefit plans in the ordinary course, Dr. Armstrong
hereby fully, forever, irrevocably and unconditionally releases, remises and discharges the Company, its officers, directors, stockholders, corporate affiliates, subsidiaries, parent companies, agents, representatives, plan administrators and
employees (each in their individual and corporate capacities) (hereinafter, the “Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts,

  

 3 

 
reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses (including
attorneys’ fees and costs), of every kind and nature which he ever had or now has against the Released Parties, including, but not limited to, any claims arising out of his employment with and/or separation from the Company, including, but not
limited to, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. § 2000e et seq., the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq., the Americans With Disabilities
Act of 1990, 42 U.S.C. §12101 et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq.,
Section 806 of the Corporate Fraud Accountability Act of 2002, 18 U.S.C. § 1514(A), the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11216, Executive Order 11141, all as amended; all claims arising out
of the Fair Credit Reporting Act, 15 U.S.C. §1681 et seq., the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. §1001 et seq., the Connecticut Human Rights and Opportunities Act, Conn. Gen.
Stat. § 46a-51 et seq., the Connecticut Equal Pay Law, Conn. Gen. Stat. § 31-75 et seq. and 31-58(e), the Connecticut Family and Medical Leave Law, Conn. Gen. Stat. § 31-51kk et seq.,
Conn. Gen. Stat. § 31-51m (Connecticut whistleblower protection law), all as amended; all common law claims including, but not limited to, actions in tort, defamation and breach of contract; all claims to any non-vested ownership
interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options; and any claim or damage arising out of his employment with or separation from the Company (including any claim for retaliation) under
any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Transition Agreement prevents him from filing, cooperating with, or participating in any proceeding
before the EEOC or a state Fair Employment Practices Agency (except that he acknowledges that he may not be able to recover any monetary benefits in connection with any such claim, charge or proceeding). 
 11. Acknowledgment. Dr. Armstrong acknowledges that he has been advised of his right to at least twenty-one (21) days to consider
this Transition Agreement and the Release of Claims at Attachment A, and that the Company advises him to consult with an attorney of his own choosing prior to signing this Transition Agreement and Attachment A. Dr. Armstrong is advised that he
may revoke his agreement for a period of seven (7) days after he signs each of the documents, and the releases provided above and at Attachment A shall not be effective or enforceable until the expiration of each such seven (7) day
revocation period. Dr. Armstrong is advised and he understands and agrees that by entering into this agreement and Attachment A and signing the Release of Claims he is waiving any and all rights or claims he might have under The Age
Discrimination in Employment Act, as amended by The Older Workers Benefit Protection Act, and that he has received consideration beyond that to which he was previously entitled. 
 12. Amendment. This Transition Agreement and Attachment A shall be binding upon the parties and may not be modified in any manner, except
by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto. This Transition Agreement and Attachment A are binding upon and shall inure to the benefit of the parties and their
respective agents, assigns, heirs, executors, successors and administrators. 
  

 4 

 13. No Waiver. No delay or omission by either party in exercising any right under this
Transition Agreement and Attachment A shall operate as a waiver of that or any other right. A waiver or consent given by a party on any one occasion shall be effective only in that instance and shall not be construed as a bar or waiver of any right
on any other occasion. 
 14. Validity. Should any provision of this Transition Agreement or Attachment A be declared or be
determined by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal and/or invalid part, term or provision shall be deemed not to be a
part of this Transition Agreement. 
 15. Continued Assistance. Dr. Armstrong agrees that after the Separation from
Service Date he will provide all reasonable cooperation to the Company, including, but not limited to, assisting the Company transition his job duties, assisting the Company in defending against and/or prosecuting any litigation or threatened
litigation, and performing any other tasks as reasonably requested by the Company, without additional compensation beyond Board fees if such services are rendered while Dr. Armstrong is a member of the Board, and at the rate of $250 per hour
following his resignation from the Board. 
 16. Cooperation. To the extent permitted by law, Dr. Armstrong agrees
to cooperate fully with the Company in the defense or prosecution of any claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company (other than those brought by
the Company against him or brought by him against the Company), whether before a state or federal court, any state or federal government agency, or a mediator or arbitrator. Dr. Armstrong’s full cooperation in connection with such claims
or actions shall include, but not be limited to, being available to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative hearing or a mediation or arbitration and to act as a witness when
requested by the Company at reasonable times designated by the Company. The Company agrees to reimburse him for reasonably necessary and documented professional time rendered following his resignation from the Board at an agreed upon hourly rate of
$250.00 in connection with such claims or actions, and shall reimburse Dr. Armstrong for travel, food, and lodging expenses. Dr. Armstrong agrees that he will notify the Company promptly in the event that he is served with a subpoena or in
the event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company. The Company agrees that, in the event of a third party claim against him, the Company will provide him
with indemnification in accordance with the terms and conditions set forth in the Company’s Amended and Restated By-Laws. 
  

 5 

 17. Voluntary Assent. Dr. Armstrong affirms that no other promises or agreements of
any kind have been made to or with him by any person or entity whatsoever to cause him to sign this Transition Agreement and Attachment A, and that he fully understands the meaning and intent of these documents. Dr. Armstrong states and
represents that he has had an opportunity to fully discuss and review the terms of this Transition Agreement and Attachment A with an attorney. Dr. Armstrong further states and represents that he has carefully read this Transition Agreement,
including Attachment A hereto, understands the contents therein, freely and voluntarily assents to all of the terms and conditions hereof, and signs his name of his own free act. 
 18. Entire Agreement. This Transition Agreement, together with Attachment A, contains and constitutes the entire understanding and
agreement between the parties hereto and cancels all previous oral and written negotiations, agreements, commitments and writings in connection therewith except as expressly provided herein. Nothing in this paragraph, however, shall modify, cancel
or supersede Dr. Armstrong’s obligations set forth in paragraph 8 above. 
  

									
	CURAGEN CORPORATION	 		 	FRANK M. ARMSTRONG, MD
				
	By:	 	/s/    Timothy M. Shannon        	 		 	/s/    Frank M. Armstrong        
	 Name:
 Title:
	 	 Timothy M. Shannon
 CEO
	 		 		 	
					
	Date:	 	September 19, 2007	 		 	Date:	 	September 19, 2007

  

 6 

 ATTACHMENT A 
 RELEASE OF CLAIMS 
 This Release of Claims forms a part of that certain Transition Agreement (the “Transition
Agreement”) dated as of                             , 2007 by and among Frank M. Armstrong, MD
(“Dr. Armstrong”), and CuraGen Corporation (the “Company”). 
 1. Dr. Armstrong’s Release of
Claims – In consideration of the payment of the benefits set forth in paragraph 3 of the Transition Agreement, which Dr. Armstrong acknowledges he would not otherwise be entitled to receive, and except with respect to benefits and
payments under this Transition Agreement or to which Dr. Armstrong is entitled under the Company’s benefit plans in the ordinary course, he hereby fully, forever, irrevocably and unconditionally releases, remises and discharges the
Company, its officers, directors, stockholders, corporate affiliates, subsidiaries, parent companies, agents, representatives, plan administrators and employees (each in their individual and corporate capacities) (hereinafter, the “Released
Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions,
obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature which he ever had or now has against the Released Parties, including, but not limited to, any claims arising out of his employment with
and/or separation from the Company, including, but not limited to, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. §2000e et seq., the Age Discrimination in Employment Act, 29 U.S.C. §
621 et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. §12101 et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”),
29 U.S.C. § 2101 et seq., Section 806 of the Corporate Fraud Accountability Act of 2002, 18 U.S.C. § 1514(A), the Rehabilitation Act of 1973, 29 U.S.C. § 701 et seq., Executive Order 11216, Executive Order 11141,
all as amended; all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. §1681 et seq., the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. §1001 et seq., the Connecticut Human Rights
and Opportunities Act, Conn. Gen. Stat. § 46a-51 et seq., the Connecticut Equal Pay Law, Conn. Gen. Stat. § 31-75 et seq. and 31-58(e), the Connecticut Family and Medical Leave Law, Conn. Gen.
Stat. § 31-51kk et seq., Conn. Gen. Stat. § 31-51m (Connecticut whistleblower protection law), all as amended; all common law claims including, but not limited to, actions in tort, defamation and breach of
contract; all claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options; and any claim or damage arising out of his employment with or separation from the
Company (including any claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above; provided, however, that nothing in this Release of Claims prevents him from filing,
cooperating with, or participating in any proceeding before the EEOC or a state Fair Employment Practices Agency (except that he acknowledges that he may not be able to recover any monetary benefits in connection with any such claim, charge or
proceeding). 
  

 7 

 2. Acknowledgement. Dr. Armstrong hereby acknowledges that he has been given at least
twenty-one (21) days to consider the Transition Agreement, as well as this Attachment A, and that the Company advises him to consult with any attorney of his own choosing prior to signing the Transition Agreement and this Attachment A.
Dr. Armstrong is advised that he may revoke his acceptance of this Attachment A during the period of seven (7) days after the execution of each of them, and this Attachment A shall not become effective or enforceable, and no severance
payments will be made pursuant to Paragraph 3 of the Transition Agreement, until this seven (7) day period has expired. Dr. Armstrong is advised and he understands and agrees that by entering into this agreement and signing these
documents and the Release of Claims he is waiving any and all rights or claims he might have under The Age Discrimination in Employment Act, as amended by The Older Workers Benefit Protection Act, and that he has received consideration beyond that
to which he was previously entitled. 
 3. Non-Disparagement. Dr. Armstrong understands and agrees that as a condition
for payment to him of the consideration herein described, he shall not make any false, disparaging or derogatory statements to any media outlet, industry group, financial institution or current or former employee, consultant, client or customer of
the Company regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company’s business affairs and financial condition, provided, however, he can give truthful statements to any state or
federal officials. 
 4. Tax Acknowledgement. In connection with the payments and consideration provided to Dr. Armstrong
pursuant to the Transition Agreement, the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and he shall be responsible for all applicable taxes with respect to such payments and consideration under
applicable law. Dr. Armstrong acknowledges that he is not relying upon the advice or representation of the Company with respect to the tax treatment of any of the payments set forth in paragraphs 2 and 3 of the Transition Agreement. 

5. Applicable Law. The Transition Agreement and this Attachment A shall be interpreted and construed by the laws of the State of
Connecticut, without regard to conflict of laws provisions. Dr. Armstrong hereby irrevocably submits to and acknowledges and recognizes the jurisdiction of the courts of the State of Connecticut or, if appropriate, a federal court located in
the State of Connecticut (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other proceeding arising out of, under or in connection with the Transition Agreement, this
Attachment A or the subject matter hereof. 
  

 8 

									
	CURAGEN CORPORATION	 		 	FRANK M. ARMSTRONG, MD
				
	By:	 	 	 		 	 
	 Name:
 Title:
	 		 		 		 	
					
	Date:	 	 	 		 	Date:	 	 

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00132-of-00352.parquet"}]]